LoxL: A Potential Cancer Drug Target and Biomarker (P42348)

Target Name: Lysyl Oxidase Homolog

NCBI ID: P42348

Lysyl Oxidase Homolog

Other Name(s): LOXL | Lysyl oxidase-like protein

LoxL: A Potential Cancer Drug Target and Biomarker

Lysyl Oxidase Homolog (LoxL) is a gene that encodes a protein known as LoxL, which is a key enzyme in the antioxidant system. LoxL is involved in the detoxification of variousxenobiotics, which are harmful substances found in the environment and in our food. The antioxidant system is a critical defense mechanism that helps our bodies eliminate harmful substances and protect against oxidative stress. Enzymes like LoxL are essential for this process, and any defects in the antioxidant system can lead to health problems.

The LoxL gene has been identified as a potential drug target in the field of cancer research. Studies have shown that LoxL is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, LoxL has been shown to be involved in the development of various types of cancer, including neurobladder cancer and melanoma.

The potential mechanisms by which LoxL contributes to cancer development are still being explored, but it is thought to work by regulating the activities of other genes involved in cancer. For example, LoxL has been shown to interact with the gene p53, which is a well-known regulator of apoptosis (programmed cell death). p53 is often activated in response to DNA damage, and it plays a critical role in preventing cancer cells from dividing and multiplying.

Another potential mechanism by which LoxL contributes to cancer development is by promoting the formation of free radicals. Free radicals are unstable molecules that can cause damage to cells and contribute to the development of oxidative stress. LoxL is involved in the production of free radicals through its role in the detoxification of xenobiotics. However, it is still not clear how LoxL promotes the formation of free radicals or how this contributes to cancer development.

In addition to its role in cancer development, LoxL is also being studied as a potential biomarker for the disease. Studies have shown that LoxL is expressed in the blood and other body tissues of individuals with various types of cancer. Additionally, LoxL has been shown to be associated with the outcomes of various types of cancer treatments, including chemotherapy and radiation therapy.

Overall, LoxL is a gene that is being actively studied as a potential drug target and biomarker for cancer. Its role in the antioxidant system and its potential contributions to cancer development make it an attractive target for researchers to explore further. Further studies are needed to fully understand the mechanisms by which LoxL contributes to cancer development and its potential as a drug target.

Protein Name: Lysyl Oxidase Homolog (nonspecified Subtype)

The "Lysyl Oxidase Homolog Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Lysyl Oxidase Homolog comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets